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ABSTRACT
Anaphylaxis is a life-threatening condition, with at-risk individuals remaining at chronic high risk of recurrence. Anaphylaxis is frequently underrecognized and undertreated by healthcare providers. The first-line pharmacologic intervention for anaphylaxis is epinephrine, and guidelines uniformly agree that its prompt administration is vital to prevent progression, improve patient outcomes, and reduce hospitalizations and fatalities. Importantly, healthcare costs potentially associated with failure to provide epinephrine (hospitalizations and emergency department visits) generally exceed those of its provision. At-risk patients are prescribed epinephrine auto-injectors to facilitate timely administration in the event of an anaphylactic episode. Despite guideline recommendations that patients carry two
auto-injectors at all times, a significant proportion of patients fail to do so, with cost of medicine cited as one reason for this lack of adherence. With the rise of highdeductible healthcare plans, patient adherence to recommendations may be further impacted by increased cost sharing. The recognition and classification of epinephrine as a preventive medicine by both the US Preventive Services Task
Force and insurers could increase patient access, improve outcomes, and save lives.
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HIGHLIGHTS
• Timely epinephrine injection prevents anaphylaxis-related hospitalization or death.
• At-risk patients should carry two epinephrine auto-injectors, but many do not.
• Prescription abandonment rates increase with higher out-of-pocket costs.
• Limited or no cost sharing is required for preventive medications.
• Classifying epinephrine auto-injectors as preventive would improve outcomes. ), and certain medications (eg, beta blockers and angiotensin-converting enzyme inhibitors).
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INTRODUCTION
5, 6
Anaphylaxis occurs on a continuum and can begin with relatively minor symptoms before progressing, in an unpredictable manner, to a life-threatening condition. 3 The most common signs and symptoms include changes in the skin (such as itching, erythema, pruritus, urticaria, angioedema) and respiration (including bronchospasm, laryngeal edema, cough, respiratory arrest); effects on the gastrointestinal, cardiovascular, and central nervous systems may also be evident. 3, 5 Anaphylaxis is often underrecognized by healthcare professionals both in general practice and in emergency care, 6 particularly if cutaneous signs and symptoms are not present (these are absent in 10-20% of patients).
International guidelines concur that anaphylaxis is a medical emergency and requires rapid intervention. 5, 6 Prompt treatment with epinephrine, the only first-line intervention for anaphylaxis, is recommended to prevent the progression of an anaphylactic episode. [4] [5] [6] 8 For patients experiencing an anaphylactic event,
epinephrine is the only medication proven to prevent hospitalization and fatalities.
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Because the onset of anaphylaxis symptoms often occurs in the community setting, at-risk patients should be prescribed epinephrine auto-injectors to provide rapid intramuscular administration of epinephrine. 4, 7, 9 However, a large number of patients prescribed epinephrine auto-injectors do not have access to one at the time of an allergen exposure, leading to delayed medication administration and increased risk of progression to severe anaphylaxis.
10-13
Currently, many high-deductible healthcare plans include epinephrine auto-injectors among those medications to which the plan's deductible applies rather than as a preventive medicine exempt from cost sharing. Because high deductibles and high cost sharing, such as those in high-deductible healthcare plans, may lead to decreased use of medical care, 14- another study reports that anaphylaxis is underrecognized in both emergency departments and urgent care centers. 30 Overall, this lack of recognition and management of anaphylaxis means that patients often do not receive first-line epinephrine treatment. For example, in a study of pediatric patients with foodinduced anaphylaxis, only 61% received epinephrine (either pre or post admission).
The median length of emergency department stay was shorter for those patients who received epinephrine prior to admission to the emergency department (3 hours vs 4
hours, P = 0.03), and these patients were also less likely to be hospitalized (17 vs 43%, P < 0.001). 27 Similarly, other studies in pediatric patients have shown that as few as 33-50% of anaphylactic patients admitted to the emergency department receive epinephrine. However, many patients do not have access to an auto-injector at the time of recurrence. In one survey, 52% of patients who had previously experienced anaphylaxis had never received a self-injectable epinephrine prescription, and 60%
did not have an auto-injector available. 10 Other authors have cited even lower figures, with an observational study reporting that only 9-28% of patients requiring epinephrine auto-injectors carried one with them. 35 In a study of 14,677 patients in a large health maintenance organization who had received a prescription for an epinephrine auto-injector, only 11% refilled consistently.
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In a survey of allergists, 38% of those who asked patients if they carried their epinephrine auto-injector indicated that one of the most frequent reasons for patients failing to carry an auto-injector was financial inability to fill the prescription. 36 Claims data also suggest that financial considerations may represent a barrier to epinephrine auto-injector use in the United States. For example, abandonment rates of the EpiPen ® auto-injector increase in relation to patient cost; more than 50% of EpiPen ® prescriptions are abandoned when patient cost exceeds $300 (Figure 1 ).
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EPINEPHRINE AUTO-INJECTOR AS A PREVENTIVE MEDICATION
The US Treasury Department defines medications as preventive "when taken by a person who has developed risk factors for a disease that has not yet manifested filling an epinephrine auto-injector prescription or visiting an allergist/immunologist) in the year before an anaphylactic event has been associated with a lower risk of severe anaphylaxis. 39 These data support the classification of epinephrine, the only first-line, life-saving treatment for anaphylaxis, as a preventive medication.
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PREVENTIVE MEDICINE AND HIGH-DEDUCTIBLE HEALTHCARE PLANS
The USPSTF is an independent, volunteer expert panel that makes evidence-based recommendations on clinical preventive procedures, services, and therapies.
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Recommendations are updated regularly, based on evidence level and cost:benefit ratio, 40 with services being graded A-D or I accordingly (Table 1) . 41 The USPSTF recommends that those services receiving grades A or B should be offered or provided to patients. Grade A services are those where there is a high certainty of substantial net benefit, and Grade B services have either a moderate certainty of moderate or substantial benefit or a high certainty of moderate benefit (Table 1) .
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11 grade preventive medications, the USPSTF evaluates all available peer-reviewed evidence, often including data from randomized controlled trials. However, in the case of some preventive medications recommended by the USPSTF (eg, folic acid for the prevention of neural tube defects), the evidence base contains only limited numbers of randomized controlled trials, due to the nature of the medication. 42 In the case of epinephrine, which was introduced prior to the advent of randomized controlled trials, 5 it would be unethical to assess efficacy in placebo-controlled or comparator randomized controlled trials (ie, it would not be ethical to withhold epinephrine when it is the only first-line medication and the only medication known to prevent fatalities).
43, 44
Partial coverage and high copayments are associated with decreased uptake of preventive services and poorer patient outcomes. 45, 46 Increased patient cost sharing is associated with decreased adherence to medications; for each dollar increase in patient copayments, adherence decreases by 0.4% on average. 14 definition of a preventive medication. For classification as preventive within a highdeductible healthcare plan policy, medications must qualify for reimbursement as part of a health savings account and cannot include those used to treat an existing illness, injury, or condition. 49 In the absence of a specific, IRS-defined list, 38 some high-deductible healthcare plan preventive medication lists can be broad and may include such medications as heart failure and diabetes medications, asthma inhalers, blood-thinning agents, and statins. [50] [51] [52] Preventive drugs and services have been shown to be cost effective in many cases, 53 and employers cite increased productivity and decreased costs among their reasons for providing preventive services coverage in employee healthcare plans. 54 One survey reported that large employers with health savings account -qualified high-deductible healthcare plans were particularly likely to use a liberal definition of preventive medications, with 57% of high-deductible healthcare plans covering preventive medications at 100% in 2013, up from 46% in 2012.
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INCLUSION OF EPINEPHRINE AUTO-INJECTOR IN HEALTHCARE PLANS
The evidence presented here suggests that the risk of epinephrine auto-injector prescription abandonment could be diminished by inclusion of epinephrine autoinjectors in preventive medication lists. A review of high-deductible healthcare plans listed under health exchanges in the Managed Markets Insight and Technology M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
13 database showed that EpiPen 2-Pak ® was classed as a tier 1-2 product in 67% of plans, classed as a tier 3-4 product in 6% of plans, "approved" in 5% of plans, and not reimbursed in 22% of plans (Table 2) . 56 However, examples of epinephrine autoinjectors being listed as preventive medications, exempt from high deductibles, in high-deductible healthcare plans are limited.
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SUMMARY AND CONCLUSIONS
Allergy is an important and prevalent condition in the United States, which puts 
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Clinical significance bullets
• Anaphylaxis is life threatening, underrecognized, and undertreated. Prompt epinephrine administration is integral to preventing hospitalizations and deaths.
• At-risk patients should carry two epinephrine auto-injectors, but many fail to do so.
• Adherence to medications decreases with the increased cost sharing associated with high-deductible healthcare plans.
• Classification of epinephrine auto-injectors as preventive medicines by the US Preventive Services Task Force and/or insurers would eliminate or reduce cost sharing, improving access and outcomes.
